GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor